J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 4, Number 1, February 2012, pages 20-25

The Importance of Cardiac Biomarkers on Remodelling After Myocardial Infarction

Figure 1. The change of tenascin-C levels between baseline and first month in all study groups. (Group 1: Total-PCI group; Group 2: Total-medical group; Group 3: Subtotal-PCI group; BL: baseline; FM: first month).

**Table 1.** Baseline Characteristics of All Patients in Three Groups
	Total-PCI Group (n: 18)	Total-Medical Group (n: 19)	Subtotal-PCI Group (n: 20)	P value
Data expressed as mean ± SD, P < 0.05 was accepted as a statistically significant. DM: diabetes mellitus; HT: hypertension; CVD: cerebrovascular disease; LDL-C: low density lipoprotein; HDL-C: high density lipoprotein; T.CHOL: total cholesterol; TG: trigliseride
Age	62 ± 12	65 ± 8	59 ± 12	0.2
Female (n, %)	5 (27)	6 (31)	6 (30)	0.9
DM (n, %)	8 (44)	9 (47)	4 (20)	0.1
HT (n, %)	9 (50)	10 (52)	6 (30)	0.3
Smoke (n, %)	11 (61)	10 (52)	12 (60)	0.8
CVD (n, %)	1 (5)	2 (10)	0	0.3
NYHA Class (n, %)
I	7 (39)	8 (42)	9 (45)	0.9
II	11(61)	11(58)	11(55)	0.9
III- IV	0	0	0
Blood Pressure(mmHg)
Diastolic	82 ± 18	85 ± 15	75 ± 11	0.1
Systolic	133 ± 23	137 ± 28	125 ± 22	0.3
Creatinine (mg/dL)	1.0 ± 0.2	1.1 ± 0.4	0.9 ± 0.1	0.1
Lipid profile (mg/dL)
LDL-C	120 ± 29	116 ± 43	118 ± 34	0.9
HDL-C	39 ± 9	41 ± 10	37 ± 8	0.4
T.CHOL	192 ± 46	183 ± 54	184 ± 42	0.8
TG	165 ± 131	129 ± 89	144 ± 80	0.5

Table 1. Baseline Characteristics of All Patients in Three Groups

Total-PCI Group (n: 18)

Total-Medical Group (n: 19)

Subtotal-PCI Group (n: 20)

P value

Data expressed as mean ± SD, P < 0.05 was accepted as a statistically significant. DM: diabetes mellitus; HT: hypertension; CVD: cerebrovascular disease; LDL-C: low density lipoprotein; HDL-C: high density lipoprotein; T.CHOL: total cholesterol; TG: trigliseride

Age

62 ± 12

65 ± 8

59 ± 12

0.2

Female (n, %)

5 (27)

6 (31)

6 (30)

0.9

DM (n, %)

8 (44)

9 (47)

4 (20)

0.1

HT (n, %)

9 (50)

10 (52)

6 (30)

0.3

Smoke (n, %)

11 (61)

10 (52)

12 (60)

0.8

CVD (n, %)

1 (5)

2 (10)

0.3

NYHA Class (n, %)

7 (39)

8 (42)

9 (45)

0.9

11(61)

11(58)

11(55)

0.9

III- IV

Blood Pressure(mmHg)

Diastolic

82 ± 18

85 ± 15

75 ± 11

0.1

Systolic

133 ± 23

137 ± 28

125 ± 22

0.3

Creatinine (mg/dL)

1.0 ± 0.2

1.1 ± 0.4

0.9 ± 0.1

0.1

Lipid profile (mg/dL)

LDL-C

120 ± 29

116 ± 43

118 ± 34

0.9

HDL-C

39 ± 9

41 ± 10

37 ± 8

0.4

T.CHOL

192 ± 46

183 ± 54

184 ± 42

0.8

165 ± 131

129 ± 89

144 ± 80

0.5

**Table 2.** The Change of Cardiac Biomarkers at Baseline and First Month in All Groups
Total- PCI Group (n = 18)	Baseline	First month	P value
Data expressed as mean ± SD, P < 0.05 was accepted as a statistically significant. NT-proBNP: N- terminal natriuretic peptide; CRP: C-reaktive protein
TENASCIN- C (ng/mL)	24 ± 12	14 ± 8	0.01
NT-PROBNP (pg/mL)	14311 ± 6962	11249 ± 5918	0.08
CRP (mg/dL)	24 ± 6	10 ± 2	0.07
Total-Medical Group (n = 19)
TENASCIN-C (ng/mL)	21 ± 8	13 ± 4	< 0.001
NT-PROBNP (pg/mL)	12284 ± 7527	3661 ± 3973	< 0.001
CRP (mg/dL)	82 ± 12	8 ± 6	0.003
Subtotal-PCI Group (n = 20)
TENASCIN-C (ng/mL)	22 ± 7	13 ± 5	< 0.001
NT-PROBNP (pg/mL)	15329 ± 6281	5305 ± 6141	< 0.001
CRP (mg/dL)	23 ± 4	5 ± 2	0.004

Table 2. The Change of Cardiac Biomarkers at Baseline and First Month in All Groups

Total- PCI Group (n = 18)

Baseline

First month

P value

Data expressed as mean ± SD, P < 0.05 was accepted as a statistically significant. NT-proBNP: N- terminal natriuretic peptide; CRP: C-reaktive protein

TENASCIN- C (ng/mL)

24 ± 12

14 ± 8

0.01

NT-PROBNP (pg/mL)

14311 ± 6962

11249 ± 5918

0.08

CRP (mg/dL)

24 ± 6

10 ± 2

0.07

Total-Medical Group (n = 19)

TENASCIN-C (ng/mL)

21 ± 8

13 ± 4

< 0.001

NT-PROBNP (pg/mL)

12284 ± 7527

3661 ± 3973

< 0.001

CRP (mg/dL)

82 ± 12

8 ± 6

0.003

Subtotal-PCI Group (n = 20)

TENASCIN-C (ng/mL)

22 ± 7

13 ± 5

< 0.001

NT-PROBNP (pg/mL)

15329 ± 6281

5305 ± 6141

< 0.001

CRP (mg/dL)

23 ± 4

5 ± 2

0.004

**Table 3.** The Change of LV Volumes and Functions Baseline to First Month in All Groups
Total- PCI Group (n = 18)	Baseline	First month	P value
Data expressed as mean ± SD, P < 0.05 was accepted as a statistically significant. LVEDV: Left ventricular enddiastolic volume; LVESV: Left ventricular endsystolic volume; LVEF: Left ventricular ejection fraction
LVESV (mL/mm²)	59 ± 27	68 ± 26	0.03
LVEDV (mL/mm²)	98 ± 35	114 ± 35	0.01
LVEF (%)	39 ± 8	40 ± 8	0.1
Total-Medical Group (n = 19)
LVESV (mL/mm²)	75 ± 23	82 ± 25	0.1
LVEDV (mL/mm²)	113 ± 27	126 ± 29	0.05
LVEF (%)	35 ± 9	36 ± 9	0.2
Subtotal-PCI Group (n = 20)
LVESV (mL/mm²)	66 ± 30	68 ± 32	0.4
LVEDV (mL/mm²)	113 ± 40	115 ± 38	0.5
LVEF (%)	42 ± 9	42 ± 9	0.3

Table 3. The Change of LV Volumes and Functions Baseline to First Month in All Groups

Total- PCI Group (n = 18)

Baseline

First month

P value

Data expressed as mean ± SD, P < 0.05 was accepted as a statistically significant. LVEDV: Left ventricular enddiastolic volume; LVESV: Left ventricular endsystolic volume; LVEF: Left ventricular ejection fraction

LVESV (mL/mm²)

59 ± 27

68 ± 26

0.03

LVEDV (mL/mm²)

98 ± 35

114 ± 35

0.01

LVEF (%)

39 ± 8

40 ± 8

0.1

Total-Medical Group (n = 19)

LVESV (mL/mm²)

75 ± 23

82 ± 25

0.1

LVEDV (mL/mm²)

113 ± 27

126 ± 29

0.05

LVEF (%)

35 ± 9

36 ± 9

0.2

Subtotal-PCI Group (n = 20)

LVESV (mL/mm²)

66 ± 30

68 ± 32

0.4

LVEDV (mL/mm²)

113 ± 40

115 ± 38

0.5

LVEF (%)

42 ± 9

0.3